Back to top

Analyst Blog

Repros Therapeutics Inc. (RPRX - Snapshot Report) recently provided an update on its phase III program for Androxal. The candidate is being evaluated for the treatment of secondary hypogonadism.

The company announced that it has completed the enrollment process for the one-year study, DEXA (ZA-303), evaluating the effects of Androxal on bone mineral density. The company completed the enrollment three months before the scheduled date. The company expects to file a New Drug Application (NDA) for Androxal primarily on the basis of data from the DEXA study by mid-2014.

The company plans to continue to enroll patients for study so that the safety requirement of minimum exposure of 800 patients for 6 months mandated by the US Food and Drug Administration (FDA) is fulfilled.

Repros Therapeutics is also conducting a six-month open label study, ZA-300 (n~500), to build a safety database as required by the FDA. The company has recruited 415 patients and expects to complete recruitment by the end of the first quarter of 2013.

We note that the Androxal phase III program also includes two pivotal phase III studies, ZA-301 and ZA-302. While the ZA-301 study is currently underway, enrollment for the ZA-302 is expected to completed shortly.

Repros Therapeutics is highly optimistic about the potential of Androxal. The company believes that the candidate offers a safer and more reliable treatment option for patients suffering from secondary hypogonadism than the currently available drugs for the disease.

We currently have a Neutral recommendation on Repros Therapeutics. The stock carries a Zacks Rank #3 (Hold) in the short run.

Pharma stocks, which currently look more attractive, are Targacept Inc. (TRGT - Snapshot Report) and Valeant Pharmaceuticals (VRX - Analyst Report). Both these companies carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
CLAYTON WIL… CWEI 117.30 +1.78%